Happenings Archive

What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.

COMPANY:

NeoStem's Phase 2 Trial Downgraded
Aug 9, 2013
Continuing site withdrawals and an unfeasible completion date earned NeoStem's (NBS) Phase 2 heart attack clinical trial a red flag downgrade from our automated Clinical Trials Monitor for the trial record's most recent update.
NeoStem's VSEL Hopes Dashed on Weissman Report
Jul 24, 2013
Renowned Stanford biologist Irving Weissman's lab reports no evidence for the existence of NeoStem's (NBS) reputed 'VSEL cells'. NBS shares were down 16% by mid-day.
NeoStem Aims to Move Uptown
Jul 23, 2013
On the heels of a recent 1:10 reverse stock split that artificially raised its share price above the magic $1 level, NeoStem (NBS) announced today it will move from the small-company exchange, NYSE MKT, to the NASDAQ effective August 5th.
Neostem (NBS) announces 1-for-10 reverse stock split; shares drop
Jul 12, 2013
On the heels of a highly dilutive and deeply discounted new share offer in April, Neostem (NBS) has announced a 1-for-10 reverse stock split effective 7/16. The company has struggled with penny-stock status since a steep drop in July of 2011. Investors registered their disappointment, sending shares down 8% by mid-day.
NeoStem (NBS) Files New Dilutive Offering; Shares Plunge
Apr 30, 2013
NeoStem's (NBS) new dilutive share offer at a discounted price displeased investors, triggering a sell-off driving shares down 21% on extremely heavy volume.
NeoStem (NBS) Receives 2nd Year of Grant Funding From NIAID
Mar 29, 2013
NeoStem (NBS) has received a second year of funding from NIH, $300K, to develop its VSEL cells for treatment of radiation-induced injury.
< Previous Page  |  Next Page >